NEW

DRUG

CONCEPTS

DESIGNING AND DEVELOPING A HEALTHIER FUTURE

“ENDECE is dedicated to the discovery and development of treatments that stop disease progression, restore function, and improve quality of life.”

James Yarger, Ph.D.

CEO

 

LATEST NEWS

ENDECE is preparing to take NDC-1308 into clinical studies. Our scientists describe the Dual Mechanism of Action (MOA) that allows NDC-1308 to directly induce an anti-inflammatory environment and directly induce remyelination within the Central Nervous System (CNS). This dual MOA allows ENDECE to treat diseases such as Neuromyelitis Optica Spectrum Disorder (NMOSD), Multiple Sclerosis (MS), Alzheimer’s Disease, and the rare disease Niemann-Pick disease type C.

NDC-1308  –  A DUAL MECHANISM OF ACTION

ANTI-INFLAMMATORY

NDC-1308 directly upregulates the Lipoprotein Lipase (LPL) gene and functional protein expression within the Central Nervous System (CNS) which polarizes macrophages to the M2-like state (pro-repair, anti-inflammatory state).

REMYELINATION

NDC-1308 directly upregulates key genes within Oligodendrocyte Progenitor Cells (OPC’s) inducing OPC differentiation to mature myelinating oligodendrocytes.